Literature DB >> 21170564

Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life.

Alberto Raggi1, Matilde Leonardi, Gennaro Bussone, Domenico D'Amico.   

Abstract

The aim of this paper is to explore the relationships between health-related quality of life (HRQoL), assessed with the Short Form-36 (SF-36), and disability in adult migraineurs using both disease-specific and generic tools, the WHO Disability Assessment Schedule II (WHO-DAS II) and with the Migraine Disability Assessment questionnaire (MIDAS). Significant differences were observed between patients with minimal/mild and moderate/severe MIDAS disability grades for Role Physical, Bodily Pain, General Health, Vitality, Social Functioning and Physical Composite Score of the SF-36; in the WHO-DAS II for household activities, participation in society and for summary score. WHO-DAS II and MIDAS provide complementary information on the intensity and the frequency of problems in performing daily activities, and could be used jointly. Our findings indicate that these issues are relevant for patients' health status and should be taken into account in future research on migraine as important secondary outcomes of treatment interventions.

Entities:  

Mesh:

Year:  2010        PMID: 21170564     DOI: 10.1007/s10072-010-0466-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

1.  Reliability of the migraine disability assessment score in a population-based sample of headache sufferers.

Authors:  W F Stewart; R B Lipton; K Kolodner; J Liberman; J Sawyer
Journal:  Cephalalgia       Date:  1999-03       Impact factor: 6.292

2.  An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score.

Authors:  W F Stewart; R B Lipton; J Whyte; A Dowson; K Kolodner; J N Liberman; J Sawyer
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

3.  Comparison of Short Form-36 and Migraine Disability Assessment questionnaire in patients with migraine.

Authors:  Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Clin J Pain       Date:  2006 Jul-Aug       Impact factor: 3.442

Review 4.  The global burden of headache: a documentation of headache prevalence and disability worldwide.

Authors:  Lj Stovner; K Hagen; R Jensen; Z Katsarava; Rb Lipton; Ai Scher; Tj Steiner; J-A Zwart
Journal:  Cephalalgia       Date:  2007-03       Impact factor: 6.292

5.  Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1).

Authors:  B C Martin; D S Pathak; M I Sharfman; J U Adelman; F Taylor; W J Kwong; P Jhingran
Journal:  Headache       Date:  2000-03       Impact factor: 5.887

6.  The impact of migraine on daily activities: effect of topiramate compared with placebo.

Authors:  Stephen D Silberstein; Elizabeth Loder; Grace Forde; George Papadopoulos; Diane Fairclough; Steven Greenberg
Journal:  Curr Med Res Opin       Date:  2006-06       Impact factor: 2.580

7.  Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Reto Agosti; Gianni Allais; Paul Bergmans; Gennaro Bussone; Brendan Davies; Mustafa Ertas; Michel Lanteri-Minet; Uwe Reuter; Margarita Sánchez Del Río; Jean Schoenen; Susanne Schwalen; Joop van Oene
Journal:  Lancet Neurol       Date:  2007-11-07       Impact factor: 44.182

Review 8.  Migraine in the United States: a review of epidemiology and health care use.

Authors:  R B Lipton; W F Stewart
Journal:  Neurology       Date:  1993-06       Impact factor: 9.910

9.  World Health Organisation Disability Assessment Schedule II: contribution to the Italian validation.

Authors:  Stefano Federici; Fabio Meloni; Alessandra Mancini; Marco Lauriola; Marta Olivetti Belardinelli
Journal:  Disabil Rehabil       Date:  2009       Impact factor: 3.033

10.  The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials.

Authors:  Carl Dahlöf; Elizabeth Loder; Merle Diamond; Marcia Rupnow; George Papadopoulos; Lian Mao
Journal:  Health Qual Life Outcomes       Date:  2007-10-04       Impact factor: 3.186

View more
  10 in total

1.  Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease.

Authors:  Alberto Raggi; Matilde Leonardi; Venusia Covelli; Alberto Albanese; Paola Soliveri; Francesco Carella; Luigi Romito
Journal:  Neurol Sci       Date:  2011-11-10       Impact factor: 3.307

Review 2.  Disability in chronic daily headache: state of the art and future directions.

Authors:  Domenico D'Amico; L Grazzi; S Usai; A Raggi; M Leonardi; G Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

3.  A longitudinal evaluation of changes in disability and quality of life in a sample of women with migraine.

Authors:  Alberto Raggi; Matilde Leonardi; Ambra Giovannetti; Marcella Curone; Gennaro Bussone; Domenico D'Amico
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

4.  Quality of life of multiple sclerosis patients with comorbid migraine.

Authors:  Veronica Villani; L Prosperini; C Pozzilli; M Salvetti; G Sette
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

Review 5.  Disability and quality of life in headache: where we are now and where we are heading.

Authors:  D D'Amico; L Grazzi; S Usai; M Leonardi; A Raggi
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

6.  A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.

Authors:  Jeffrey L Jackson; Elizabeth Cogbill; Rafael Santana-Davila; Christina Eldredge; William Collier; Andrew Gradall; Neha Sehgal; Jessica Kuester
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

7.  Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.

Authors:  Jeffrey L Jackson; Akira Kuriyama; Yachiyo Kuwatsuka; Sarah Nickoloff; Derek Storch; Wilkins Jackson; Zhi-Jiang Zhang; Yasuaki Hayashino
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

8.  Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.

Authors:  Janet H Ford; David W Ayer; Qi Zhang; Jeffrey N Carter; Elizabeth Leroux; Vladimir Skljarevski; Sheena K Aurora; Antje Tockhorn-Heidenreich; Richard B Lipton
Journal:  Neurology       Date:  2019-07-03       Impact factor: 9.910

9.  Alterations in regional homogeneity assessed by fMRI in patients with migraine without aura stratified by disease duration.

Authors:  Ling Zhao; Jixin Liu; Xilin Dong; Yulin Peng; Kai Yuan; Fumei Wu; Jinbo Sun; Qiyong Gong; Wei Qin; Fanrong Liang
Journal:  J Headache Pain       Date:  2013-10-17       Impact factor: 7.277

10.  Discriminative Analysis of Migraine without Aura: Using Functional and Structural MRI with a Multi-Feature Classification Approach.

Authors:  Qiongmin Zhang; Qizhu Wu; Junran Zhang; Ling He; Jiangtao Huang; Jiang Zhang; Hua Huang; Qiyong Gong
Journal:  PLoS One       Date:  2016-09-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.